New hope for AML patients: gentler drug combo could replace harsh chemo
Disease control
Not yet recruiting
This study compares a new drug combination (venetoclax plus azacitidine) against standard chemotherapy for adults with a specific type of acute myeloid leukemia (AML) that has NPM1 or IDH mutations. About 148 people will be randomly assigned to one of the two treatments. The main…
Phase: PHASE2 • Sponsor: Shen yang • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC